Close

We use cookies to improve your experience of our website. Privacy Policy

Skip to main content
Menu

Project

Development of a synovium-chondrocyte organ-on-a-chip model with integrated biomechanical stimulation

Emulate Organ-chip
Emulate Organ-chip
Primary
Investigator:
Prof Hazel Screen
Queen Mary University of London
Co-investigators:Dr Clare Thompson
Queen Mary University of London
 Prof Martin Knight
Queen Mary University of London
Funder:EPSRC OA Tech Network Plus - Pump Priming Grant
Project dates:01-01-2019 to 30-04-2022
Centre dates:01-01-2021 to 01-09-2021

Mechanical loading is essential to the health and maintenance of articular cartilage; the connective tissue covering bone surfaces within the joint. The processes of matrix production and catabolism are carefully balanced in response to mechanical queues arising from physical activity. Disruption of this balance leads to the development of osteoarthritis (OA) which is characterised by the progressive destruction, and eventual loss of the cartilage. This is associated with pain, reduced joint function and loss of mobility and represents a significant cost for health services. However there is currently no treatment available that can halt cartilage destruction. This results from a lack of understanding of the disease as existing models are too simple and do not include the full synovial joint or the mechanical environment it experiences.

In this proposal we plan to develop an organ-on-a chip (OOAC) model of the joint to provide a solution to this. OOAC refers to a multi-channel 3D microfluidic cell culture chip, which can simulate the physiological response of whole organs, in this case the synovial joint. This joint chip will incorporate the multiple cell types seen in cartilage and the surrounding synovial environment to mimic human tissue architecture, cellular microenvironment and signalling. Most importantly, this system will permit the mechanical stimulation of the cultured cells as a single unit finally giving us the potential to test drug candidates in a more physiologically representative system. Not only will this model have the benefit of reducing the use of mouse models in research, it will revolutionise the safety and efficacy testing of healthcare products in arthritis and permit the rapid identification of novel drugs for treating arthritis.